Enantioselective total syntheses of plectosphaeroic acids B and C

Journal of Organic Chemistry

Volumn 78, Issue 17, 2013, Pages 8766-8788

  Jabri, Salman Y ^a   Overman, Larry E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C-N BOND FORMATIONS; CARBOXYLATE COMPLEXES; ENANTIOSELECTIVE; ENANTIOSELECTIVE TOTAL SYNTHESIS; MARINE ALKALOIDS; STEREO-SELECTIVE; SYNTHETIC STRATEGIES; TOTAL SYNTHESIS;

AMINATION; CARBOXYLATION; ENANTIOSELECTIVITY; POLYCYCLIC AROMATIC HYDROCARBONS;

SYNTHESIS (CHEMICAL);

ALKALOID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PLECTOSPHAEROIC ACID B; PLECTOSPHAEROIC ACID C; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CHEMICAL BOND; CROSS COUPLING REACTION; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; HUMAN CELL; STEREOCHEMISTRY;

INDOLE ALKALOIDS; MOLECULAR CONFORMATION; STEREOISOMERISM;

EID: 84883772268     PISSN: 00223263     EISSN: 15206904     Source Type: Journal    
DOI: 10.1021/jo4015479     Document Type: Article

References (98)

1. Gardiner, D. M.; Waring, P.; Howlett, B. J. Microbiology 2005, 151, 1021-1032
2. Jiang, C.-S.; Guo, Y.-W. Mini-Rev. Med. Chem. 2011, 11, 728-745
3. Iwasa, E.; Hamashima, Y.; Sodeoka, M. Isr. J. Chem. 2011, 51, 420-433
4. Jiang, C.-S.; Müller, W. E. G.; Schröder, H. C.; Guo, Y.-W. Chem. Rev. 2012, 112, 2179-2207
5. Vigushin, D. M.; Mirsaidi, N.; Brooke, G.; Sun, C.; Pace, P.; Inman, L.; Moody, C. J.; Coombes, R. C. Med. Oncol. 2004, 21, 21-30
6. Boyer, N. C.; Morrison, K. C.; Kim, J.; Hergenrother, P. J.; Movassaghi, M. Chem. Sci. 2013, 4, 1646-1657
7. DeLorbe, J. E.; Horne, D.; Jove, R.; Mennen, S. M.; Nam, S.; Zhang, F.-L.; Overman, L. E. J. Am. Chem. Soc. 2013, 135, 4117-4128
8. Waring, P.; Eichner, R. D.; Müllbacher, A. Med. Res. Rev. 1988, 8, 499-524
9. Kung, A. L. Cancer Cell 2004, 6, 33-43
10. Isham, C. R.; Tibodeau, J. D.; Jin, W.; Xu, R.; Timm, M. M.; Bible, K. C. Blood 2007, 109, 2579-2588
11. Lee, Y.-M.; Lim, J.-H.; Yoon, H.; Chun, Y.-S.; Park, J.-W. Hepatology 2011, 53, 171-180
12. Chaib, H.; Nebbioso, A.; Preber, T.; Castellano, R.; Garbit, S.; Restouin, A.; Vey, N.; Altucci, L.; Collette, Y. Leukemia 2012, 26, 662-674 and ref 2a
13. Carr, G.; Tay, W.; Bottriell, H.; Andersen, S. K.; Mauk, A. G.; Andersen, R. J. Org. Lett. 2009, 11, 2996-2999
14. Nagarajan, R.; Woody, R. W. J. Am. Chem. Soc. 1973, 95, 7212-7222 see also ref 2c
15. Libot, F.; Miet, C.; Kunesch, N.; Poisson, J. E.; Pusset, J.; Sévenet, T. J. Nat. Prod. 1987, 50, 468-473
16. Lebsack, A. D.; Link, J. T.; Overman, L. E.; Stearns, B. A. J. Am. Chem. Soc. 2002, 124, 9008-9009
17. For structure determination and total synthesis, see: Foo, K.; Newhouse, T.; Mori, I.; Takayama, H.; Baran, P. S. Angew. Chem., Int. Ed. 2011, 50, 2716-2719
18. Takahashi, C.; Numata, A.; Ito, Y.; Matsumura, E.; Araki, H.; Iwaki, H.; Kushida, K. J. Chem. Soc., Perkin Trans. 1 1994, 1859-1864
19. Feng, Y.; Blunt, J. W.; Cole, A. L. J.; Munro, M. H. G. J. Nat. Prod. 2004, 67, 2090-2092
20. Usami, Y.; Yamaguchi, J.; Numata, A. Heterocycles 2004, 63, 1123-1129
21. Dong, J.-Y.; He, H.-P.; Shen, Y.-M.; Zhang, K.-Q. J. Nat. Prod. 2005, 68, 1510-1513
22. Zheng, C.-J.; Kim, C.-J.; Bae, K. S.; Kim, Y.- H.; Kim, W.-G. J. Nat. Prod. 2006, 69, 1816-1819
23. Bertinetti, B. V.; Rodriguez, M. A.; Godeas, A. M.; Cabrera, G. M. J. Antibiot. 2010, 63, 681-683
24. Li, L.; Li, D.; Luan, Y.; Gu, Q.; Zhu, T. J. Nat. Prod. 2012, 75, 920-927
25. Wang, F.-Z.; Huang, Z.; Shi, X.-F.; Chen, Y.-C.; Zhang, W.-M.; Tian, X.-P. Bioorg. Med. Chem. Lett. 2012, 22, 7265-7267
26. Hollstein, U. Chem. Rev. 1974, 74, 625-652
27. Graves, D. E. In Sequence-specific DNA Binding Agents; Waring, M. J., Ed.; RSC Publishing: Cambridge, 2006; pp 109-129.
28. Bolognese, A.; Correale, G.; Manfra, M.; Lavecchia, A.; Novellino, E.; Pepe, S. J. Med. Chem. 2006, 49, 5110-5118
29. Le Roes-Hill, M.; Goodwin, C.; Burton, S. Trends Biotechnol. 2009, 27, 248-258
30. Estlin, E. J.; Veal, G. J. Cancer Treat. Rev. 2003, 29, 253-273
31. Muller, A. J.; Prendergast, G. C. Curr. Cancer Drug Targets 2007, 7, 31-40
32. For a recent summary of the varied structural types that inhibit IDO, see: Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Nature Rev. Drug Discovery 2013, 12, 64-82
33. 50 of cinnabarinic acid (4) was reported to be 0.46 μM, compared with 2 μM reported earlier;(4) see: Pasceri, R.; Siegel, D.; Ross, D.; Moody, C. J. J. Med. Chem. 2013, 56, 3310-3317
34. For total syntheses of (+)-gliocladin C (19) and (+)-gliocladine C (6), see: DeLorbe, J. E.; Jabri, S. Y.; Mennen, S. M.; Overman, L. E.; Zhang, F.-L. J. Am. Chem. Soc. 2011, 133, 6549-6552
35. Boyer, N.; Movassaghi, M. Chem. Sci. 2012, 3, 1798-1803
36. Coste, A.; Adams, T. C.; Movassaghi, M. Chem. Sci. 2013, 4, 3191-3197
37. Nicolaou, K. C.; Totokotsopoulos, S.; Giguère, D.; Sun, Y.-P.; Sarlah, D. J. Am. Chem. Soc. 2011, 133, 8150-8153
38. Codelli, J. A.; Puchlopek, A. L. A.; Reisman, S. E. J. Am. Chem. Soc. 2012, 134, 1930-1933
39. Nicolaou, K. C.; Lu, M.; Totokotsopoulos, S.; Heretsch, P.; Giguère, D.; Sun, Y.-P.; Sarlah, D.; Nguyen, T. H.; Wolf, I. C.; Smee, D. F.; Day, C. W.; Bopp, S.; Winzeler, E. A. J. Am. Chem. Soc. 2012, 134, 17320-17332
40. For an example of portmanteau inhibitors, see: Wang, Z.; Bennett, E. M.; Wilson, D. J.; Salomon, C.; Vince, R. J. Med. Chem. 2007, 50, 3416-3419
41. The total synthesis of (+)-plectosphaeroic acid B was described in a preliminary communication; see: Jabri, S. Y.; Overman, L. E. J. Am. Chem. Soc. 2013, 135, 4231-4234
42. Minato, H.; Matsumoto, M.; Katayama, T. Chem. Commun. 1971, 44-45
43. Minato, H.; Matsumoto, M.; Katayama, T. J. Chem. Soc., Perkin Trans. 1 1973, 1819-1825
44. Overman, L. E.; Shin, Y. Org. Lett. 2007, 9, 339-341
45. Iwasa, E.; Hamashima, Y.; Fujishiro, S.; Higuchi, E.; Ito, A.; Yoshida, M.; Sodeoka, M. J. Am. Chem. Soc. 2010, 132, 4078-4079
46. Fujishiro, S.; Dodo, K.; Iwasa, E.; Teng, Y.; Sohtome, Y.; Hamashima, Y.; Ito, A.; Yoshida, M.; Sodeoka, M. Bioorg. Med. Chem. Lett. 2013, 23, 733-736
47. See ref 2c and: Overman, L. E.; Sato, T. Org. Lett. 2007, 9, 5267-5270
48. The Movassaghi group has described strategies for controlled introduction of two to four sulfur atoms into the bridge of ETP natural products; see: Kim, J.; Movassaghi, M. J. Am. Chem. Soc. 2010, 132, 14376-14378
49. Brewer, D.; Rahman, R.; Safe, S.; Taylor, A. Chem. Commun 1968, 1571
50. Safe, S.; Taylor, A. J. Chem. Soc. C 1970, 432-435
51. Ley, S. V.; Thomas, A. W. Angew. Chem., Int. Ed. 2003, 42, 5400-5449
52. Evano, G.; Blanchard, N.; Toumi, M. Chem. Rev. 2008, 108, 3054-3131
53. Hartwig, J. F. Acc. Chem. Res. 2008, 41, 1534-1544
54. Monnier, F.; Taillefer, M. Angew. Chem., Int. Ed. 2009, 48, 6954-6971
55. Surry, D. S.; Buchwald, S. L. Chem. Sci. 2010, 1, 13-31
56. Surry, D. S.; Buchwald, S. L. Chem. Sci. 2011, 2, 27-50
57. Maiti, D.; Fors, B. P.; Handerson, J. L.; Nakamura, Y.; Buchwald, S. L. Chem. Sci. 2011, 2, 57-68
58. Fischer, C.; Koenig, B. Beilstein J. Org. Chem. 2011, 7, 59-74
59. Rosen, B. M.; Quasdorf, K. W.; Wilson, D. A.; Zhang, N.; Resmerita, A. M.; Garg, N. K.; Percec, V. Chem. Rev. 2011, 111, 1346-1416
60. To the best of our knowledge, molecules containing a 2-aminophenoxazin-3- one fragment had not prior to our studies been reported to participate in a transition-metal-catalyzed cross-coupling reaction. In addition, at the outset of our work, bimolecular arylation of the indoline nitrogen of a cyclotryptamine to our knowledge had not been described. However, during our studies, two reports appeared; see ref 7 and: Snell, R. H.; Durbin, M. J.; Willis, M. C.; Woodward, R. L. Chem.-Eur. J. 2012, 18, 16754-16764
61. Richard, D. J.; Schiavi, B.; Joullié, M. M. Proc. Nat. Acad. Sci. U.S.A. 2004, 101, 11971-11976
62. Hewitt, P. R.; Cleator, E.; Ley, S. V. Org. Biomol. Chem. 2004, 2, 2415-2417
63. Furst, L.; Narayanam, J. M. R.; Stephenson, C. R. J. Angew. Chem., Int. Ed. 2011, 50, 9655-9659
64. Sun, M.; Hao, X.-Y.; Liu, S.; Hao, X.-J. Tetrahedron Lett. 2013, 54, 692-694
65. Ruan, J. W.; Huang, Z. S.; Huang, J. F.; Du, C. J.; Huang, S. L.; Shi, Z.; Fu, L. W.; Gu, C. Q. Chin. Chem. Lett. 2006, 17, 1141-1144
66. Giurg, M.; Piekielska, K.; GeÌ̈bala, M.; Ditkowski, B.; Wolański, M.; Peczyńska-Czoch, W.; Mlochowski, J. Synth. Commun. 2007, 37, 1779-1789 and references therein.
67. Wolfe, J. P.; Wagaw, S.; Marcoux, J.-F.; Buchwald, S. L. Acc. Chem. Res. 1998, 31, 805-818
68. Hartwig, J. F. Angew. Chem., Int. Ed. 1998, 37, 2046-2067
69. Fairfax, D. K.; Yang, Z. Benzoxazole Carboxamides for Treating CINV and IBS-D. US Patent 2006/183769 A1, 08/17/ 2006. See the Experimental Section for details.
70. Osman, A.; Bassioumi, I. J. Am. Chem. Soc. 1960, 82, 1607-1609
71. Manthey, M. K.; Pyne, S. G; Truscott, R. J. W. Biochem. Biophys. Acta 1990, 1034, 207-210
72. Christen, S.; Southwell-Keely, P. T.; Stocker, R. Biochemistry 1992, 31, 8090-8097
73. Allred, G. D.; Liebeskind, L. S. J. Am. Chem. Soc. 1996, 118, 2748-2749
74. Li, G.; Padwa, A. Org. Lett. 2011, 13, 3767-3769
75. Kubo, T.; Katoh, C.; Yamada, K.; Okano, K.; Tokuyama, H.; Fukuyama, T. Tetrahedron 2008, 64, 11230-11236
76. Komori, T.; Satoh, N.; Yokoshima, S.; Fukuyama, T. Syn Lett. 2011, 13, 1859-1862
77. Hentges, S. G.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 4263-4265
78. For previous use of CuOAc in C-N cross-couplings, see ref 37 and: Bellina, F.; Calandri, C.; Cauteruccio, S.; Rossi, R. Eur. J. Org. Chem. 2007, 2147-2151
79. Herscheid, J. D. M.; Tijhuis, M. W.; Noordik, J. H.; Ottenheijm, H. C. J. J. Am. Chem. Soc. 1979, 101, 1159-1162
80. Fukuyama, T.; Nakatsuka, S.-I.; Kishi, Y. Tetrahedron 1981, 37, 2045-2078
81. For the lability of aminophenoxazinones, see: Bolognese, A.; Piscitelli, C.; Scherillo, G. J. Org. Chem. 1983, 48, 3649-3652
82. Zhao, H.; Pendri, A.; Greenwald, R. B. J. Org. Chem. 1998, 63, 7559-7562
83. McMurry, J. E. Org. React 1976, 24, 187-224
84. Murdock, K. C. J. Med. Chem. 1974, 17, 827-835
85. Ottenheijm, H. C. J.; Herscheid, J. D. M.; Kerkhoff, G. P. C.; Spande, T. F. J. Org. Chem. 1976, 41, 3433-3438
86. Coffen, D. L.; Katonak, D. A.; Nelson, N. R.; Sancilio, F. D. J. Org. Chem. 1977, 42, 948-952
87. Curtis, P. J.; Greatbanks, D.; Hesp, B.; Cameron, A. F.; Freer, A. A. J. Chem. Soc., Perkin Trans. 1 1977, 180-189
88. Kirby, G. W.; Rao, G. V.; Robins, D. J.; Stark, W. M. Tetrahedron Lett. 1986, 27, 5539-5540
89. Pedras, M. S. C.; Séguin-Swartz, G.; Abrams, A. R. Phytochemistry 1990, 29, 777-782
90. Pickering, T. L.; Saunders, K. J.; Tobolsky, A. V. J. Am. Chem. Soc. 1967, 89, 2364-2367
91. Hino, T.; Sato, T. Chem. Pharm. Bull. 1974, 22, 2866-2874
92. Herscheid, J. D. M.; Tijhuis, M. W.; Noordik, J. H.; Ottenheijm, H. C. J. J. Am. Chem. Soc. 1979, 101, 1159-1162
93. Fisher, J. W.; Trinkle, K. L. Tetrahedron Lett. 1994, 35, 2505-2508
94. Cell viability was determined by Dr. Sangkil Nam at the Beckman Research Institute, City of Hope Comprehensive Cancer Center, using a MTS metabolic activity assay as described by the supplier (Promega); see: Nam, S.; Williams, A.; Vultur, A.; List, A.; Bhalla, K.; Smith, D.; Lee, F. Y.; Jove, R. Mol. Cancer Ther. 2007, 6, 1400-1405
95. Node, M.; Kawabata, T.; Ohta, K.; Fujimoto, M.; Fujita, E.; Fuji, K. J. Org. Chem. 1984, 49, 3641-3643
96. Angyal, S. J.; Bullock, E. B.; Hangar, W. E.; Howell, W. C.; Johnson, A. W. J. Chem. Soc. 1952, 1592-1602
97. Bolognese, A.; Piscitelli, C.; Scherillo, G. J. Org. Chem. 1983, 48, 3649-3652
98. The procedure for preparation of 3-hydroxyanthranilic acid methyl ester from 3-hydroxyanthranilic acid has been described; see: Fielder, D. A.; Collins, F. W. J. Nat. Prod. 1995, 58, 456-458